Autoantibodies in pancreatic ductal adenocarcinoma
2023
Cold Spring Harbor Laboratory, New York, USA
Over 90 percent of pancreatic cancer cases are recognised as an aggressive, fatal form of the disease known as pancreatic ductal adenocarcinoma (PDAC). In this study, the researchers planned to discover a novel antigen found in PDAC tumours only. Detecting a new PDAC antigen may aid explanations of why some patients have more favourable outcomes than others. The authors used single-cell RNA sequencing (scRNA-Seq) and immunoglobulin (Ig) sequencing of tumor-infiltrating immune cells from 7 primary human PDAC samples. The results show that plasma cells in PDAC produce autoantibodies reacting with intracellular self-antigens, which may result from promotion of pre-existing, autoreactive B cell responses. These observations indicate the chronic inflammatory microenvironment of PDAC can support the adaptive immune response.
Plasma cells in human pancreatic ductal adenocarcinoma secrete antibodies against self-antigens
Douglas T. Fearon
Added on: 01-26-2024
[1] https://insight.jci.org/articles/view/172449[2] https://www.drugtargetreview.com/news/112927/pancreatic-cancer-initiates-an-immune-system-response/?utm_source=Email+marketing&utm_medium=email&utm_campaign=DTR+-+Industry+Insight+-+Sinobiological+-++Antibodies+-+12.01.24&utm_term=Utilising+CAAR+T+cells+to+treat+antibody-caused+brain+disease&utm_content=https%3a%2f%2femails.drugtargetreview.com%2frussellpublishinglz%2f&gator_td=HgqHSV3vZ4yBfiuAJWHezq0BByA0dIjcvZWYUM3V4KcNGiEYbso%2bXO16Yi10RY4wU43hULLh%2fPee3JbqLBHCOf%2b8BuXiIRCTe1uXVKhnAqFSk2LcTmqt5TtagfvWNmINtfy0jqw3p2nPUnqF9NXvhFx9ay3sah45%2bvqkzCA7LoOPvb4ZPy8QfLqxa2h1pJCX14ukqwJThqkzlU7o%2bWwzFVGBDzNb5s%2frB8CzoNkwTFXgMjXCnffWs6iSt%2bRhtP6zD1NfDZBacBKBpZ8PTfTJxg%3d%3d
